Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
Price:
3.07
USD
-5.25%
Market Cap:
$45.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
|
US |
|
S
|
Synel MLL Payway Ltd
TASE:SNEL
|
IL |
|
P
|
POET Technologies Inc
NASDAQ:POET
|
CA |
|
Big Rock Brewery Inc
TSX:BR
|
CA |
|
C
|
Cosco Capital Inc
XPHS:COSCO
|
PH |
|
Guangzhou KingTeller Technology Co Ltd
SZSE:002177
|
CN |
|
Starbreeze AB
STO:STAR B
|
SE |
|
Collins Foods Ltd
ASX:CKF
|
AU |
|
M
|
MNtech Co Ltd
KOSDAQ:095500
|
KR |
|
Aligos Therapeutics Inc
NASDAQ:ALGS
|
US |
|
H
|
Hangzhou Everfine Photo-e-info Co Ltd
SZSE:300306
|
CN |
|
Huangshan Tourism Development Co Ltd
SSE:600054
|
CN |
|
Genex Power Ltd
ASX:GNX
|
AU |
|
Odyssey Acquisition SA
F:2XA
|
LU |
|
I
|
IRSA Inversiones y Representaciones SA
BCBA:IRSA
|
AR |
|
Shanghai LongYun Cultural Creation & Technology Group Co Ltd
SSE:603729
|
CN |
|
S
|
Sabuy Technology PCL
SET:SABUY
|
TH |
|
Mercantile Ventures Ltd
BSE:538942
|
IN |
|
H
|
Heiq PLC
LSE:HEIQ
|
UK |
|
Strix Group PLC
LSE:KETL
|
IM |
|
Asana Inc
NYSE:ASAN
|
US |
|
Maharah for Human Resources Company SJSC
SAU:1831
|
SA |
|
U
|
UCAL Ltd
NSE:UCAL
|
IN |
|
Comsys Holdings Corp
TSE:1721
|
JP |
Balance Sheet
Balance Sheet Decomposition
Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc
Balance Sheet
Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc
Currency: USD
| Dec-2005 | Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||||
| Cash & Cash Equivalents |
6
|
6
|
11
|
12
|
79
|
66
|
71
|
54
|
41
|
40
|
38
|
35
|
45
|
28
|
28
|
25
|
27
|
20
|
18
|
18
|
11
|
|
| Cash Equivalents |
6
|
6
|
11
|
12
|
79
|
66
|
71
|
54
|
41
|
40
|
38
|
35
|
45
|
28
|
28
|
25
|
27
|
20
|
18
|
18
|
11
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
17
|
14
|
15
|
15
|
16
|
5
|
8
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
2
|
5
|
2
|
3
|
6
|
5
|
7
|
6
|
5
|
6
|
6
|
7
|
8
|
8
|
10
|
12
|
7
|
13
|
10
|
12
|
17
|
|
| Accounts Receivables |
2
|
5
|
2
|
3
|
6
|
5
|
7
|
6
|
5
|
6
|
6
|
7
|
8
|
8
|
10
|
12
|
7
|
13
|
10
|
12
|
17
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
1
|
1
|
1
|
2
|
5
|
8
|
6
|
6
|
6
|
6
|
4
|
5
|
7
|
12
|
9
|
11
|
8
|
10
|
5
|
4
|
6
|
|
| Other Current Assets |
0
|
1
|
1
|
1
|
3
|
2
|
4
|
4
|
4
|
5
|
4
|
3
|
4
|
3
|
3
|
2
|
3
|
3
|
3
|
3
|
2
|
|
| Total Current Assets |
9
|
13
|
15
|
18
|
93
|
81
|
87
|
87
|
69
|
71
|
67
|
66
|
69
|
59
|
50
|
50
|
46
|
46
|
36
|
36
|
37
|
|
| PP&E Net |
0
|
0
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
4
|
3
|
1
|
6
|
7
|
6
|
9
|
|
| PP&E Gross |
0
|
0
|
1
|
0
|
1
|
1
|
0
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
4
|
3
|
1
|
6
|
7
|
6
|
9
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
0
|
2
|
3
|
3
|
3
|
3
|
3
|
4
|
4
|
2
|
2
|
2
|
3
|
|
| Intangible Assets |
0
|
10
|
9
|
9
|
8
|
7
|
7
|
10
|
16
|
22
|
21
|
22
|
21
|
34
|
31
|
28
|
24
|
31
|
23
|
18
|
14
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
|
| Other Long-Term Assets |
1
|
4
|
5
|
4
|
2
|
2
|
0
|
1
|
3
|
2
|
3
|
5
|
3
|
18
|
19
|
15
|
12
|
10
|
15
|
14
|
12
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Assets |
10
N/A
|
27
+160%
|
29
+9%
|
31
+8%
|
104
+233%
|
92
-11%
|
96
+4%
|
99
+3%
|
88
-11%
|
95
+9%
|
92
-4%
|
93
+2%
|
93
0%
|
113
+21%
|
105
-7%
|
97
-8%
|
84
-12%
|
93
+10%
|
82
-12%
|
76
-8%
|
77
+2%
|
|
| Liabilities | ||||||||||||||||||||||
| Accounts Payable |
1
|
3
|
2
|
3
|
6
|
2
|
2
|
3
|
2
|
3
|
3
|
8
|
9
|
11
|
12
|
13
|
10
|
11
|
14
|
14
|
19
|
|
| Accrued Liabilities |
1
|
1
|
3
|
3
|
4
|
4
|
5
|
5
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
2
|
2
|
2
|
2
|
2
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
2
|
3
|
1
|
9
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
|
| Other Current Liabilities |
1
|
2
|
0
|
1
|
0
|
0
|
0
|
0
|
6
|
11
|
10
|
7
|
9
|
15
|
9
|
10
|
7
|
16
|
12
|
11
|
16
|
|
| Total Current Liabilities |
3
|
9
|
8
|
8
|
19
|
9
|
7
|
8
|
8
|
14
|
12
|
15
|
18
|
28
|
24
|
26
|
19
|
29
|
28
|
32
|
37
|
|
| Long-Term Debt |
0
|
4
|
1
|
6
|
11
|
5
|
5
|
4
|
0
|
0
|
2
|
4
|
10
|
20
|
19
|
15
|
15
|
16
|
13
|
10
|
5
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
1
|
3
|
3
|
0
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
9
|
11
|
9
|
8
|
12
|
12
|
11
|
10
|
|
| Total Liabilities |
4
N/A
|
15
+295%
|
12
-21%
|
14
+11%
|
32
+132%
|
14
-55%
|
13
-12%
|
13
+2%
|
8
-37%
|
15
+80%
|
15
+3%
|
20
+35%
|
29
+44%
|
57
+95%
|
53
-6%
|
50
-7%
|
42
-16%
|
57
+36%
|
52
-8%
|
53
+1%
|
52
-1%
|
|
| Equity | ||||||||||||||||||||||
| Common Stock |
18
|
18
|
20
|
16
|
68
|
71
|
70
|
67
|
63
|
62
|
57
|
55
|
52
|
51
|
50
|
49
|
48
|
47
|
47
|
47
|
52
|
|
| Retained Earnings |
12
|
7
|
3
|
2
|
5
|
7
|
13
|
19
|
16
|
19
|
20
|
19
|
12
|
5
|
1
|
2
|
6
|
11
|
17
|
24
|
27
|
|
| Total Equity |
6
N/A
|
11
+79%
|
17
+50%
|
18
+5%
|
72
+311%
|
78
+8%
|
83
+7%
|
86
+3%
|
80
-7%
|
81
+2%
|
77
-5%
|
73
-5%
|
64
-12%
|
56
-13%
|
51
-8%
|
47
-8%
|
43
-9%
|
36
-15%
|
30
-18%
|
23
-23%
|
25
+9%
|
|
| Total Liabilities & Equity |
10
N/A
|
27
+160%
|
29
+9%
|
31
+8%
|
104
+233%
|
92
-11%
|
96
+4%
|
99
+3%
|
88
-11%
|
95
+9%
|
92
-4%
|
93
+2%
|
93
0%
|
113
+21%
|
105
-7%
|
97
-8%
|
84
-12%
|
93
+10%
|
82
-12%
|
76
-8%
|
77
+2%
|
|
| Shares Outstanding | ||||||||||||||||||||||
| Common Shares Outstanding |
10
|
10
|
10
|
10
|
20
|
20
|
20
|
19
|
18
|
17
|
16
|
16
|
16
|
16
|
15
|
15
|
15
|
14
|
14
|
14
|
15
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
